M. Frénay

3.3k total citations
42 papers, 2.4k citations indexed

About

M. Frénay is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, M. Frénay has authored 42 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 16 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in M. Frénay's work include Glioma Diagnosis and Treatment (25 papers), Brain Metastases and Treatment (14 papers) and Meningioma and schwannoma management (10 papers). M. Frénay is often cited by papers focused on Glioma Diagnosis and Treatment (25 papers), Brain Metastases and Treatment (14 papers) and Meningioma and schwannoma management (10 papers). M. Frénay collaborates with scholars based in France, United States and Netherlands. M. Frénay's co-authors include Johan M. Kros, Martin J. van den Bent, Alba A. Brandes, Luc Taillandier, Hugues Duffau, Olivier Chinot, Khê Hoang‐Xuan, Roger Stupp, G. Milano and Denys Fontaine and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

M. Frénay

42 papers receiving 2.4k citations

Peers

M. Frénay
Knut Lote Norway
Andrew A. Kanner Israel
Soichiro Shibui Japan
Masayuki Kanamori Japan
Teri Kreisl United States
Felix Bokstein Israel
Fumiyuki Yamasaki Japan
Camilo E. Fadul United States
Rakesh Jalali India
Lyndon Kim United States
Knut Lote Norway
M. Frénay
Citations per year, relative to M. Frénay M. Frénay (= 1×) peers Knut Lote

Countries citing papers authored by M. Frénay

Since Specialization
Citations

This map shows the geographic impact of M. Frénay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Frénay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Frénay more than expected).

Fields of papers citing papers by M. Frénay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Frénay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Frénay. The network helps show where M. Frénay may publish in the future.

Co-authorship network of co-authors of M. Frénay

This figure shows the co-authorship network connecting the top 25 collaborators of M. Frénay. A scholar is included among the top collaborators of M. Frénay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Frénay. M. Frénay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bourg, Véronique, Laurent Suissa, Lydiane Mondot, et al.. (2018). Bevacizumab: Is the lower the better for glioblastoma patients in progression?. Bulletin du Cancer. 105(12). 1135–1146. 4 indexed citations
2.
3.
Capelle, Laurent, Denys Fontaine, Emmanuel Mandonnet, et al.. (2013). Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases. Journal of neurosurgery. 118(6). 1157–1168. 293 indexed citations
4.
Lebrun‐Frénay, Christine, Patrick Vermersch, David Brassat, et al.. (2011). Cancer and multiple sclerosis in the era of disease-modifying treatments. Journal of Neurology. 258(7). 1304–1311. 51 indexed citations
5.
Bourg, V., M. Frénay, Mikaël Cohen, et al.. (2011). Le bévacizumab dans le traitement des radionécroses cérébrales. Revue Neurologique. 167(4). 331–336. 10 indexed citations
6.
7.
Soffietti, Riccardo, Brigitta G. Baumert, Lorenzo Bello, et al.. (2010). Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force. European Journal of Neurology. 17(9). 1124–1133. 362 indexed citations
8.
Bondiau, Pierre‐Yves, Ender Konukoğlu, Olivier Clatz, et al.. (2010). Biocomputing: Numerical simulation of glioblastoma growth and comparison with conventional irradiation margins. Physica Medica. 27(2). 103–108. 22 indexed citations
9.
Castelli, J., Juliette Thariat, Karen Bénézery, et al.. (2009). Tumeurs spinales et paraspinales traitées par irradiation stéréotaxique par CyberKnife® au centre Antoine-Lacassagne de Nice. Cancer/Radiothérapie. 14(1). 5–10. 6 indexed citations
10.
Pallud, Johan, Hugues Duffau, P Barbarino-Monnier, et al.. (2009). Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group. Journal of Neurology. 256(12). 2014–2020. 37 indexed citations
11.
Bondiau, Pierre‐Yves, Olivier Clatz, Maxime Sermesant, et al.. (2008). Biocomputing: numerical simulation of glioblastoma growth using diffusion tensor imaging. Physics in Medicine and Biology. 53(4). 879–893. 49 indexed citations
12.
Lebrun‐Frénay, Christine, Denys Fontaine, V. Bourg, et al.. (2007). Treatment of newly diagnosed symptomatic pure low‐grade oligodendrogliomas with PCV chemotherapy. European Journal of Neurology. 14(4). 391–398. 43 indexed citations
13.
Lebrun‐Frénay, Christine, et al.. (2004). Chimiothérapie néoadjuvante dans les astrocytomes fibrillaires de grade II symptomatiques non opérables de l’adulte. Revue Neurologique. 160(5). 533–537. 4 indexed citations
14.
Bent, Martin J. van den, Alba A. Brandes, Johan Menten, et al.. (2003). Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology. 21(13). 2525–2528. 223 indexed citations
15.
Marcy, Pierre-Yves, et al.. (2002). Cost–benefit assessment of inferior vena cava filter placement in advanced cancer patients. Supportive Care in Cancer. 10(1). 76–80. 14 indexed citations
16.
Chanalet, S., et al.. (1997). Solitary meningeal plasmacytomas. Annals of Oncology. 8(8). 791–795. 7 indexed citations
17.
Chatel, M., Christine Lebrun‐Frénay, & M. Frénay. (1993). Chemotherapy and immunotherapy in adult malignant gliomas. Current Opinion in Oncology. 5(3). 464–473. 10 indexed citations
18.
Milano, G., M C Etienne, E. Cassuto‐Viguier, et al.. (1992). Influence of sex and age on fluorouracil clearance.. Journal of Clinical Oncology. 10(7). 1171–1175. 213 indexed citations
19.
Etienne, Marie‐Christine, G. Milano, M. Strolin Benedetti, et al.. (1991). Improved Bioavailability of a New Oral Preparation of Medroxyprogesterone Acetate. Journal of Pharmaceutical Sciences. 80(12). 1130–1132. 7 indexed citations
20.
Khayat, D., Jean-Pierre Bizzari, M. Frénay, et al.. (1988). Interim Report of Phase II Study of New Nitrosourea S 10036 in Disseminated Malignant Melanoma. JNCI Journal of the National Cancer Institute. 80(17). 1407–1408. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Knut Lote Breakdown of academic impact, for papers by Andrew A. Kanner Breakdown of academic impact, for papers by Soichiro Shibui Breakdown of academic impact, for papers by Masayuki Kanamori Breakdown of academic impact, for papers by Teri Kreisl Breakdown of academic impact, for papers by Felix Bokstein Breakdown of academic impact, for papers by Fumiyuki Yamasaki Breakdown of academic impact, for papers by Camilo E. Fadul Breakdown of academic impact, for papers by Rakesh Jalali Breakdown of academic impact, for papers by Lyndon Kim
Rankless by CCL
2026